

16.2.1 Discontinued Participants

Listing 16.2.1.1 Subject Disposition Randomized Set

Listing 16.2.1.2 Screen Failure Subject Subjects Screen Failed

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011030	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011042	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (29)	
US2011043	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011056	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011057	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011060	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011064	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2011067	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011068	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011069	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011070	2020-05-28	AMENDMENT 1	No/ 2020-08-06 (63)	Lost to Follow-Up		Yes/ 2020-07-06 (32)	
US2011086	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011088	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (34)	
US2021061	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2021062	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2021073	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021078	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2021082	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	
US2021089	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (31)	
US2021094	2020-05-28	AMENDMENT 1	ONGOING			No/ 2020-07-13 (39)	Adverse Event (COVID-19 Infection)
US2021096	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (30)	
US2021107	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (30)	
US2021111	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-21 (44)	
US2021135	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021137	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2021138	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (33)	
US2021144	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (32)	
US2021155	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (36)	
US2021161	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2021162	2020-06-03	AMENDMENT 1	ONGOING			No/ 2020-06-08 (1)	Other/ FALSE POSITIVE COVID RESULT REPORTED FROM CENTRAL LAB
US2021175	2020-06-04	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (31)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031001	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (33)	
US2031009	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (31)	
US2031014	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (32)	
US2031022	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (32)	
US2031023	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (35)	
US2031029	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	
US2031038	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (30)	
US2031040	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031041	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2031043	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2031045	2020-05-27	AMENDMENT 1	No/ 2020-07-13 (42)	Lost to Follow-Up		No/ 2020-07-13 (42)	Lost to Follow-Up
US2031048	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2031049	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (31)	
US2031058	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (31)	
US2031071	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2031074	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031081	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2041005	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-26 (29)	
US2041011	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (31)	
US2041014	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-26 (29)	
US2041019	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041020	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2041022	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (32)	
US2041025	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041029	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2041034	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (32)	
US2041042	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (36)	
US2041043	2020-05-28	AMENDMENT 1	No/ 2020-07-17 (45)	Lost to Follow-Up		No/ 2020-07-17 (45)	Lost to Follow-Up
US2041056	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041059	2020-05-28	AMENDMENT 1	No/ 2020-07-27 (56)	Lost to Follow-Up		No/ 2020-07-27 (56)	Lost to Follow-Up
US2041062	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041078	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041086	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (29)	
US2041089	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (33)	
US2041090	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (33)	
US2051022	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	
US2051035	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (35)	
US2051036	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	
US2051044	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (32)	
US2061003	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (33)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2061015	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	
US2061018	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (34)	
US2061021	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2061022	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (30)	
US2061025	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2061032	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2071012	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	
US2071014	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071017	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2071022	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (30)	
US2071042	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (36)	
US2071044	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	
US2071046	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (34)	
US2071049	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (35)	
US2071050	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2071059	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071062	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (34)	
US2071064	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (35)	
US2071066	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (30)	
US2071070	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2071072	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (32)	
US2081026	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (34)	
US2081033	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	
US2081038	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081042	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (29)	
US2081046	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	
US2081049	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (30)	
US2081057	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (35)	
US2081058	2020-06-04	AMENDMENT 1	ONGOING			No/ 2020-06-17 (10)	Other/ PER CRA, POSITIVE COVID SWAB WAS REPORTED IN ERROR BY PPD LABS. PATIENT IS NO LONGER WITHIN WINDOW TO RECEIVE 2ND DOSE.

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011020	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (31)	
US2011029	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011048	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011051	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (35)	
US2011055	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011061	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (30)	
US2011084	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011087	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011090	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2011091	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2011092	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2011093	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (29)	
US2011095	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (32)	
US2011102	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (29)	
US2021058	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2021064	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021084	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2021090	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (35)	
US2021147	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2021166	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2021167	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2021179	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2031002	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (32)	
US2031004	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031011	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (34)	
US2031016	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2031030	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2031042	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (33)	
US2031051	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2031056	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2031057	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2031063	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031066	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2031072	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	
US2031080	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2041002	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041003	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041006	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	
US2041007	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2041012	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041013	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (32)	
US2041016	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-14 (43)	
US2041023	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2041027	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2041030	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2041036	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041047	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041049	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-14 (41)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041051	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041053	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	
US2041055	2020-05-28	AMENDMENT 1	No/ 2020-07-17 (45)	Lost to Follow-Up		No/ 2020-07-17 (45)	Lost to Follow-Up
US2041058	2020-05-28	AMENDMENT 1	No/ 2020-07-17 (45)	Lost to Follow-Up		No/ 2020-07-17 (45)	Lost to Follow-Up
US2041064	2020-05-28	AMENDMENT 1	No/ 2020-08-18 (72)	Lost to Follow-Up		Yes/ 2020-07-14 (37)	
US2041071	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (35)	
US2041075	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2041076	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (35)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041077	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2041088	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (33)	
US2041091	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (31)	
US2041092	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-14 (37)	
US2051008	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (33)	
US2051009	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2051010	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2051011	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051018	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2051027	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2051031	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2051032	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2051033	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (34)	
US2051034	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051038	2020-05-29	AMENDMENT 1	No/ 2020-07-02 (30)	Withdrawal of Consent (COVID-19 Non-Infection Related)/ PATIENT WITHDREW FROM STUDY- DID NOT WANT TO PROCEED.		No/ 2020-07-02 (30)	Withdrawal of Consent (COVID-19 Non-Infection Related)/ DID NOT WANT TO PROCEED- PATIENT WITHDREW FROM STUDY
US2051040	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2051042	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2051043	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2051048	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (32)	
US2051050	2020-06-04	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (31)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2061001	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (37)	
US2061006	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2061009	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	
US2061011	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	
US2061013	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (32)	
US2061019	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2061026	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2071001	2020-05-22	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (33)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071003	2020-05-22	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2071004	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (35)	
US2071029	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (36)	
US2071030	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	
US2071032	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (33)	
US2071033	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	
US2071063	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (36)	
US2071067	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (34)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071074	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	
US2071081	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2081036	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (36)	
US2081039	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (31)	
US2081041	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (34)	
US2081052	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (35)	
US2081054	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (34)	
US2081059	2020-06-04	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (36)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011018	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2011019	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	
US2011039	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011041	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011046	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2011050	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011059	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2011065	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011080	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2011085	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2011089	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (36)	
US2011103	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2021059	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	
US2021063	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (34)	
US2021067	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (32)	
US2021068	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021074	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	
US2021080	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (34)	
US2021093	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	
US2021099	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2021101	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	
US2021121	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2021145	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (36)	
US2021151	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021154	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (34)	
US2021164	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (31)	
US2021180	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (31)	
US2021182	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2031012	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2031013	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2031019	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (35)	
US2031020	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (34)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031021	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2031026	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-26 (29)	
US2031027	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2031033	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2031035	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2031037	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2031047	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2031050	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031060	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2031062	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2031073	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	
US2031079	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2031084	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (29)	
US2041008	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (31)	
US2041010	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (32)	
US2041024	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041026	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041041	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (36)	
US2041046	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2041048	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2041060	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2041061	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (35)	
US2041073	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2041079	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041080	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2041084	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2051001	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2051002	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	
US2051003	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-23 (26)	
US2051012	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2051013	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (29)	
US2051017	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051019	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (29)	
US2051020	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (29)	
US2051024	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	
US2051025	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (35)	
US2051026	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2051028	2020-05-28	AMENDMENT 1	ONGOING			No/ 2020-06-15 (12)	Other/ FALSE POSITIVE COVID INFECTION RESULTED BY CENTRAL LAB
US2051029	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (36)	

* indicates re-screen subjects.
Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051030	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	
US2051045	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (29)	
US2061008	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	
US2061010	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (36)	
US2061020	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2061023	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (32)	
US2061024	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (30)	
US2061027	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (34)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071002	2020-05-22	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2071016	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (36)	
US2071026	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (36)	
US2071036	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (36)	
US2071038	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (40)	
US2071039	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (39)	
US2071040	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (36)	
US2071051	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071068	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (31)	
US2071069	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (36)	
US2071071	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (33)	
US2071073	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (30)	
US2071077	2020-06-03	AMENDMENT 1	ONGOING			Yes/ 2020-07-10 (33)	
US2081023	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	
US2081025	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	
US2081028	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081045	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (34)	
US2081051	2020-06-02	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (34)	
US2081062	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	
US2081063	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (31)	
US2081064	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011007	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011011	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-26 (29)	
US2011023	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	
US2011109	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011114	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011116	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (31)	
US2011120	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (31)	
US2011124*	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011126*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011130*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011131	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011142*	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2011145	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011152	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2011155	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2011156	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011157*	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2021015	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-26 (29)	
US2021021	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-26 (29)	
US2021022	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (36)	
US2021043	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (32)	
US2021130	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2021185	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (36)	
US2021189	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021196	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (33)	
US2021198	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (37)	
US2021206*	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (34)	
US2021207*	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-08-06 (42)	
US2021219*	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (32)	
US2021222*	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	
US2031085	2020-06-08	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2031089	2020-06-08	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031092	2020-06-08	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (30)	
US2031095	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2031098	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	
US2031100	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (34)	
US2031102	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (33)	
US2031103	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (32)	
US2031110	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2031116	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031124	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	
US2031125	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2031129	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (30)	
US2031131	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	
US2041102	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2041114	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (39)	
US2041115	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (35)	
US2041121	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (31)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041132	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2041142	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	
US2041146	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	
US2041151	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	
US2041152	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (29)	
US2041166	2020-07-01	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2051055	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (35)	
US2051063	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051072	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2051073	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-08-05 (31)	
US2051086	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	
US2051087	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	
US2051089	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (29)	
US2051098	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-08-05 (31)	
US2051112	2020-07-01	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2061035	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-07-20 (25)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2061043	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2061046	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2061051	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (31)	
US2061055	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2071005	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (35)	
US2071041	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (31)	
US2071084	2020-06-05	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2071085	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071086	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2071088*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2071092	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-07-21 (26)	
US2071094	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	
US2071098	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-05 (36)	
US2071100	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	
US2071102	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (30)	
US2071103	2020-06-26	AMENDMENT 1	ONGOING			Yes/ 2020-08-06 (36)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071105	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-08-10 (36)	
US2081004	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (32)	
US2081005	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (31)	
US2081007	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2081015	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (31)	
US2081017	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (35)	
US2081029	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	
US2081030	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (35)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081065	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2081066	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2081073	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2081077	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (35)	
US2081080	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (31)	
US2081087	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (30)	
US2081097	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (31)	
US2081103	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-08-06 (36)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081104	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-08-06 (36)	
US2081113	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-10 (34)	
US2081119	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-11 (37)	
US2081125	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (33)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011012	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2011014	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011032	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2011040	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011117	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011123*	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011125*	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (28)	
US2011127*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011137*	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011138*	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (31)	
US2011153*	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2021004	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-26 (29)	
US2021012	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2021018	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-13 (46)	
US2021019	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (35)	
US2021020	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021045	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2021047	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2021133	2020-06-01	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2021190	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2021192	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2021205*	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (36)	
US2021216*	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (33)	
US2021217*	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021220*	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	
US2021226	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	
US2031086	2020-06-08	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2031096	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2031097	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (35)	
US2031104	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (36)	
US2031105	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2031106	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031107	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2031108	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2031109	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2031114	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (29)	
US2031121	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2031128	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (29)	
US2041094	2020-06-08	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2041100	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041103	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2041104	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2041106	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2041109	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2041111	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2041113	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2041118	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (30)	
US2041119	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041127	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2041130	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2041139	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (30)	
US2041145	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	
US2041150	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (34)	
US2041155	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2051057	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2051059	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051060	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2051066	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2051068	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2051071	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2051078	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (30)	
US2051081	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2051092	2020-06-26	AMENDMENT 1	ONGOING			Yes/ 2020-08-06 (31)	
US2051093	2020-06-26	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051094	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (29)	
US2051095	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (29)	
US2051096	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2051099	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2051100	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (34)	
US2051103	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (29)	
US2051105	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	
US2051107	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051109	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	
US2061037	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2061053	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (29)	
US2061057	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (29)	
US2061064	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2061068	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (32)	
US2071007	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (36)	
US2071024	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071025	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-07-08 (36)	
US2071083*	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-21 (26)	
US2071090	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	
US2071099	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (29)	
US2071101	2020-06-25	AMENDMENT 1	No/ 2020-09-14 (78)	Lost to Follow-Up		Yes/ 2020-08-03 (36)	
US2071104	2020-06-26	AMENDMENT 1	ONGOING			Yes/ 2020-08-10 (36)	
US2071106	2020-07-01	AMENDMENT 1	ONGOING			No/ 2020-07-11 (6)	Other/ LOG LINE #1- COVID 19 POSITIVE

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081003	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (32)	
US2081009	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-02 (32)	
US2081020	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (28)	
US2081070	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2081071	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (30)	
US2081085	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-08-11 (40)	
US2081090	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (34)	
US2081092	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081100	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (33)	
US2081110	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (29)	
US2081112	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-11 (40)	
US2081118	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (31)	
US2081123	2020-06-25	AMENDMENT 1	ONGOING			No/ 2020-08-11 (43)	Adverse Event (Other) / AE LOGLINE #1

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011004	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011009	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011028	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2011113	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (29)	
US2011118	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011121	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (29)	
US2011122	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011128*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2011139	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2011149*	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2011159	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (29)	
US2011162	2020-07-01	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2021003	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (33)	
US2021007	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2021011	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-26 (29)	
US2021031	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021114	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2021115	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (36)	
US2021186	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2021208*	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (29)	
US2021211*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (30)	
US2021214*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2021215*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (36)	
US2021218*	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2021230	2020-07-01	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2021232	2020-07-02	AMENDMENT 1	ONGOING			Yes/ 2020-08-06 (32)	
US2021234	2020-07-02	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (29)	
US2031091	2020-06-08	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2031093	2020-06-08	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (31)	
US2031101	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (36)	
US2031111	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2031112	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2031122	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	
US2041096	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (30)	
US2041107	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2041108	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2041112	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2041117	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2041120	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2041122	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	

* indicates re-screen subjects.
Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2041123	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2041125	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (30)	
US2041126	2020-06-12	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2041131	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-08-10 (43)	
US2041136	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (34)	
US2041138	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2041144	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2041149	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051054	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2051064	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (29)	
US2051069	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2051070	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (34)	
US2051074	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2051075	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (30)	
US2051077	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (30)	
US2051084	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051085	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (29)	
US2051088	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2051097	2020-06-29	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2051101	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-08-10 (36)	
US2051102	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (29)	
US2051104	2020-06-30	AMENDMENT 1	No/ 2020-09-02 (58)	Lost to Follow-Up		No/ 2020-08-11 (36)	Adverse Event (Other)/ AE #1, #2, AND #3
US2051106	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2051108	2020-06-30	AMENDMENT 1	ONGOING			Yes/ 2020-08-10 (36)	
US2051111	2020-07-01	AMENDMENT 1	ONGOING			Yes/ 2020-08-04 (30)	
US2061036	2020-06-09	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2061045	2020-06-10	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (29)	
US2061063	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (29)	
US2071006	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2071013	2020-05-25	AMENDMENT 1	ONGOING			Yes/ 2020-07-09 (38)	
US2071037	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-07-07 (35)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2071043	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-07-06 (34)	
US2071082	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (33)	
US2071087	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-30 (35)	
US2071089*	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2071091	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-07-27 (32)	
US2071093	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	
US2071095	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-28 (30)	
US2071096*	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-05 (35)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081001	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-24 (27)	
US2081002	2020-05-26	AMENDMENT 1	ONGOING			Yes/ 2020-06-25 (28)	
US2081014	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (30)	
US2081016	2020-05-27	AMENDMENT 1	ONGOING			Yes/ 2020-06-29 (29)	
US2081019	2020-05-28	AMENDMENT 1	ONGOING			Yes/ 2020-06-30 (29)	
US2081035	2020-05-29	AMENDMENT 1	ONGOING			Yes/ 2020-07-01 (30)	
US2081069	2020-06-11	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	
US2081072	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-24 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081075	2020-06-15	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (30)	
US2081076	2020-06-16	AMENDMENT 1	ONGOING			Yes/ 2020-08-05 (36)	
US2081081	2020-06-17	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	
US2081088	2020-06-18	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (33)	
US2081091	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (32)	
US2081093	2020-06-19	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (33)	
US2081099	2020-06-22	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (34)	
US2081108	2020-06-23	AMENDMENT 1	ONGOING			Yes/ 2020-07-31 (29)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.1
Subject Disposition
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Informed Consent Date	Protocol Version	Completed Study/ Date of Study Discontinuation/ Completion (Day)	Reason for Study Discontinuation/ Specified Reason	Date of Death/ Autopsy Performed?	Completed Dosing/ Date of Dosing Discontinuation/ Completion (Day)	Primary Reason for Dosing Discontinuation/ Specified Reason
US2081116	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (31)	
US2081117	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-11 (37)	
US2081120	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-07-29 (29)	
US2081121	2020-06-24	AMENDMENT 1	ONGOING			Yes/ 2020-08-10 (36)	
US2081129	2020-06-25	AMENDMENT 1	ONGOING			Yes/ 2020-08-03 (33)	

* indicates re-screen subjects.

Day is defined as study day from first injection date.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020101.sas 19NOV2020 01:21 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011001	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011003	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011005	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC10: History of chronic smoking (≥ 1 cigarette a day) within 1 year of the Screening Visit (Day 0)	
US2011006	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011008	2020-05-26	AMENDMENT 1	Withdrew Consent	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011015	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011021	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011022	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011024	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011027	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011033	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011034	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC15: Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma)	
US2011035	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011037	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011045	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2011049	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011052	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2011053	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC22: Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011054	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011062	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011063	2020-05-28	AMENDMENT 1	Cohort Full	
US2011066	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011071	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011072	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011074	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011075	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011076	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011077	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011078	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2011079	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011083	2020-05-29	AMENDMENT 1	Withdrew Consent	
US2011094	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011096	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011097	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC15: Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma)	
US2011098	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2011099	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011100	2020-06-04	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011101	2020-06-04	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011104	2020-06-08	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011105	2020-06-08	AMENDMENT 1	Cohort Full	
US2011106	2020-06-09	AMENDMENT 1	Cohort Full	
US2011107	2020-06-09	AMENDMENT 1	Cohort Full	
US2011108	2020-06-09	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011111	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011112	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011115	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011119	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0); INC03: According to the assessment of the investigator, is in good general health and can comply with study procedures.	
US2011132*	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ INC02: Understands and agrees to comply with the study procedures and provides written informed consent.	
US2011133	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011134	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011135	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011136	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011140*	2020-06-22	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011143	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011144	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011146*	2020-06-24	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2011147	2020-06-24	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011148	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011150*	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2011151	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011154*	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011158*	2020-06-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011160	2020-06-30	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2011161	2020-07-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021001	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021002	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021005	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021008	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2021009	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021013	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC09: Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors); EXC10: History of chronic smoking (≥ 1 cigarette a day) within 1 year of the Screening Visit (Day 0)	
US2021014	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC21: Anticipating the need for immunosuppressive treatment at any time during participation in the study	
US2021017	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2021025	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021026	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	
US2021027	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2021028	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	
US2021030	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021032	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021033	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021034	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021036	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021037	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021038	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2021041	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021048	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.; INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021049	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2021050	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	
US2021051	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2021052	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ INC03: According to the assessment of the investigator, is in good general health and can comply with study procedures.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021053	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021054	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2021055	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021056	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021057	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021060	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021065	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021066	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021069	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ INC03: According to the assessment of the investigator, is in good general health and can comply with study procedures.	
US2021071	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021072	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021075	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021077	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2021079	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021081	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021083	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021085	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2021086	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ INC02: Understands and agrees to comply with the study procedures and provides written informed consent.	
US2021087	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021088	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021091	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.; EXC09: Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors); EXC10: History of chronic smoking (>= 1 cigarette a day) within 1 year of the Screening Visit (Day 0)	
US2021092	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC09: Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors); EXC10: History of chronic smoking (>= 1 cigarette a day) within 1 year of the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021095	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021097	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021098	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021100	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021102	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021103	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.; INC03: According to the assessment of the investigator, is in good general health and can comply with study procedures.	
US2021105	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021108	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2021109	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021110	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021112	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2021113	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021116	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021117	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2021118	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021119	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021120	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021122	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC15: Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma)	
US2021123	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021124	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021125	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021126	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021127	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC14: Diabetes mellitus	
US2021128	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021129	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC15: Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma)	
US2021131	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021132	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021134	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2021136	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021139	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021140	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021141	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021142	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC20: Received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening Visit. Topical tacrolimus is allowed if not used <=14 days prior to Screening Visit	
US2021143	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021146	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021148	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021149	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021150	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021152	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021153	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021156	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021157	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021158	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021159	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021160	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021163	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021165	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021168	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2021169	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ INC03: According to the assessment of the investigator, is in good general health and can comply with study procedures.	
US2021170	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021171	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021172	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021173	2020-06-04	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021174	2020-06-04	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021176	2020-06-04	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021177	2020-06-05	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021178	2020-06-05	AMENDMENT 1	Cohort Full	
US2021181	2020-06-05	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021183	2020-06-05	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021184	2020-06-10	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021187	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2021188	2020-06-11	AMENDMENT 1	Cohort Full	
US2021191	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021193	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2021194	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021195	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2021197	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2021199	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ INC03: According to the assessment of the investigator, is in good general health and can comply with study procedures.	
US2021201	2020-06-15	AMENDMENT 1	Withdrew Consent	
US2021202*	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021203	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021204	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2021209*	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021210*	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021212	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021213*	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021221	2020-06-29	AMENDMENT 1	Cohort Full	
US2021223	2020-06-29	AMENDMENT 1	Inclusion/Exclusion/ EXC01: Known history of SARS-CoV-2 infection or known exposure to someone with SARS-CoV-2 infection or COVID-19	
US2021224	2020-06-30	AMENDMENT 1	Inclusion/Exclusion/ EXC25: Diagnosis of malignancy within previous 10 years (excluding non-melanoma skin cancer)	
US2021225	2020-06-30	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021227	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC22: Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0)	
US2021228	2020-07-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021229	2020-07-01	AMENDMENT 1	Cohort Full	
US2021231	2020-07-02	AMENDMENT 1	Cohort Full	
US2021233	2020-07-02	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2021235	2020-07-06	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2021236	2020-07-06	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021237	2020-07-06	AMENDMENT 1	Cohort Full	
US2021238	2020-07-06	AMENDMENT 1	Cohort Full	
US2021239	2020-07-06	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2021240	2020-07-07	AMENDMENT 1	Cohort Full	
US2021241	2020-07-07	AMENDMENT 1	Inclusion/Exclusion/ EXC29: Participated in an interventional clinical study within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study.	
US2031003	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031005	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2031006	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2031007	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031008	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC01: Known history of SARS-CoV-2 infection or known exposure to someone with SARS-CoV-2 infection or COVID-19	
US2031010	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031015	2020-05-26	AMENDMENT 1	Cohort Full	
US2031017	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031018	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031024	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031025	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2031028	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031031	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031032	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2031034	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031036	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031039	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031044	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031046	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ INC06: Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol.	
US2031052	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031053	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031054	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2031055	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031059	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2031061	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2031064	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031065	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031067	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2031068	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031069	2020-05-29	AMENDMENT 1	Cohort Full	
US2031070	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2031075	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031076	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031077	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031078	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC10: History of chronic smoking (≥ 1 cigarette a day) within 1 year of the Screening Visit (Day 0)	
US2031082	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031083	2020-06-05	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031087	2020-06-08	AMENDMENT 1	Inclusion/Exclusion/ EXC14: Diabetes mellitus	
US2031088	2020-06-08	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2031090	2020-06-08	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031099	2020-06-09	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031113	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2031115	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031117	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2031118	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2031119	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031120	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031123	2020-06-17	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2031126	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC15: Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma)	
US2031127*	2020-06-22	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031130	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2031132	2020-06-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2031133	2020-07-02	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2031134	2020-07-06	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2031135	2020-07-06	AMENDMENT 1	Cohort Full	
US2031136	2020-07-07	AMENDMENT 1	Cohort Full	
US2041001	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041004	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ INC02: Understands and agrees to comply with the study procedures and provides written informed consent.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041009	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041015	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041017	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2041018	2020-05-26	AMENDMENT 1	Cohort Full	
US2041021	2020-05-26	AMENDMENT 1	Cohort Full	
US2041028	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041031	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041032	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041033	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2041035	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041037	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2041038	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2041039	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC28: Has donated >= 450 mL of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study.	
US2041040	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041044	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2041045	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2041050	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2041052	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041054	2020-05-28	AMENDMENT 1	Cohort Full	
US2041057	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041063	2020-05-28	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041065	2020-05-28	AMENDMENT 1	Cohort Full	
US2041066	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041067	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041068	2020-05-28	AMENDMENT 1	Cohort Full	
US2041069	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC28: Has donated >= 450 mL of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study.	
US2041070	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041072	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC10: History of chronic smoking (≥ 1 cigarette a day) within 1 year of the Screening Visit (Day 0)	
US2041074	2020-05-29	AMENDMENT 1	Withdrew Consent	
US2041081	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041082	2020-06-01	AMENDMENT 1	Withdrew Consent	
US2041083	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m ² to 30 kg/m ² (inclusive) at the Screening Visit (Day 0)	
US2041085	2020-06-04	AMENDMENT 1	Cohort Full	
US2041087	2020-06-05	AMENDMENT 1	Cohort Full	
US2041093	2020-06-08	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041095	2020-06-09	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041097	2020-06-09	AMENDMENT 1	Cohort Full	
US2041098	2020-06-09	AMENDMENT 1	Cohort Full	
US2041099	2020-06-09	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2041101	2020-06-10	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041105	2020-06-10	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041110	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041116	2020-06-11	AMENDMENT 1	Cohort Full	
US2041124	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2041128	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041129	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041133	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041134	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2041135	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2041137	2020-06-15	AMENDMENT 1	Cohort Full	
US2041140	2020-06-16	AMENDMENT 1	Cohort Full	
US2041141	2020-06-16	AMENDMENT 1	Cohort Full	
US2041143	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ EXC22: Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0)	
US2041147	2020-06-17	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041148	2020-06-17	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2041153	2020-06-23	AMENDMENT 1	Cohort Full	
US2041154	2020-06-25	AMENDMENT 1	Cohort Full	
US2041156	2020-06-29	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2041157	2020-06-29	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2041158	2020-06-30	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041159	2020-06-30	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	
US2041160	2020-06-30	AMENDMENT 1	Cohort Full	
US2041161	2020-07-01	AMENDMENT 1	Cohort Full	
US2041162	2020-07-01	AMENDMENT 1	Cohort Full	
US2041163	2020-07-01	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2041164	2020-07-01	AMENDMENT 1	Cohort Full	
US2041165	2020-07-01	AMENDMENT 1	Cohort Full	
US2041167	2020-07-01	AMENDMENT 1	Cohort Full	
US2041168	2020-07-01	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2041169	2020-07-02	AMENDMENT 1	Cohort Full	
US2041170	2020-07-07	AMENDMENT 1	Cohort Full	
US2041171	2020-07-07	AMENDMENT 1	Cohort Full	
US2041172	2020-07-07	AMENDMENT 1	Cohort Full	
US2051004	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC21: Anticipating the need for immunosuppressive treatment at any time during participation in the study	
US2051005	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051006	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2051007	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051014	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ INC02: Understands and agrees to comply with the study procedures and provides written informed consent.	
US2051015	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051016	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051021	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2051023	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0); EXC21: Anticipating the need for immunosuppressive treatment at any time during participation in the study	
US2051037	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC11: History of illegal substance use or alcohol abuse within the past 2 years. This does not apply to historical cannabis use that was formerly illegal in participant's state but is legal at Screening.	
US2051039	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051041	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2051046	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2051047	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051049	2020-06-04	AMENDMENT 1	Cohort Full	
US2051051	2020-06-09	AMENDMENT 1	Cohort Full	
US2051052	2020-06-09	AMENDMENT 1	Cohort Full	
US2051053	2020-06-10	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2051056	2020-06-12	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2051058	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051061	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051062	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ INC02: Understands and agrees to comply with the study procedures and provides written informed consent.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2051065	2020-06-17	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051067	2020-06-17	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.; INC03: According to the assessment of the investigator, is in good general health and can comply with study procedures.	
US2051076	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2051079	2020-06-22	AMENDMENT 1	Other	ENROLLMENT CLOSED

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2051080	2020-06-22	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051082	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051083	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051090	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2051091	2020-06-26	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2051110	2020-07-01	AMENDMENT 1	Other	ENROLLMENT CLOSED
US2061002	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061004	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2061005	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0); EXC22: Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0)	
US2061007	2020-05-28	AMENDMENT 1	Withdrew Consent	
US2061012	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061014	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2061016	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061017	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061028	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061029	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061030	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2061031	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC09: Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors)	
US2061033	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061034	2020-06-05	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061038	2020-06-09	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061039	2020-06-10	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2061040	2020-06-10	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061041	2020-06-10	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061042	2020-06-10	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061044	2020-06-10	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061047	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2061048	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061049	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061050	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061052	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061054	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2061056	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061058	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ INC03: According to the assessment of the investigator, is in good general health and can comply with study procedures.	
US2061059	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061060	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061061	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2061062	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061065	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061066	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2061067	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061069	2020-06-24	AMENDMENT 1	Inclusion/Exclusion/ EXC15: Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2061070	2020-06-29	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2061071	2020-06-30	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2061072	2020-07-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2071008	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2071009	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2071010	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2071011	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2071015	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2071018	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC09: Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2071019	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC14: Diabetes mellitus	
US2071020	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2071021	2020-05-25	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2071023	2020-05-26	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2071027	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC22: Positive serology for hepatitis B virus surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) type 1 or 2 antibodies identified at the Screening Visit (Day 0)	
US2071028	2020-05-26	AMENDMENT 1	Cohort Full	
US2071034	2020-05-27	AMENDMENT 1	Other	SUBJECT WAS SCREENED AS A SENTINEL SUBJECT AND VISIT WINDOW CLOSED BEFORE DAY 1 VISIT. SUBJECT IS A SF AND WILL BE RESCREENED WHEN COHORT 2 OPENS AGAIN.
US2071035	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2071045	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2071048	2020-05-28	AMENDMENT 1	Other	EXCLUSION
US2071053	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC29: Participated in an interventional clinical study within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study.	
US2071054	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/	
US2071055	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ INC02: Understands and agrees to comply with the study procedures and provides written informed consent.	
US2071056	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2071058	2020-06-01	AMENDMENT 1	Cohort Full	
US2071060	2020-06-01	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2071061	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2071065	2020-06-01	AMENDMENT 1	Cohort Full	
US2071075	2020-06-02	AMENDMENT 1	Cohort Full	
US2071076	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2071078	2020-06-03	AMENDMENT 1	Cohort Full	
US2071079	2020-06-04	AMENDMENT 1	Cohort Full	
US2071080	2020-06-05	AMENDMENT 1	Cohort Full	
US2071097	2020-06-24	AMENDMENT 1	Inclusion/Exclusion/	
US2081006	2020-05-26	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081008	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2081010	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2081011	2020-05-27	AMENDMENT 1	Cohort Full	
US2081012	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC14: Diabetes mellitus	
US2081013	2020-05-27	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	
US2081018	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease; EXC25: Diagnosis of malignancy within previous 10 years (excluding non-melanoma skin cancer)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081021	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC16: Chronic cardiovascular disease	
US2081022	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC20: Received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening Visit. Topical tacrolimus is allowed if not used <=14 days prior to Screening Visit	
US2081024	2020-05-28	AMENDMENT 1	Inclusion/Exclusion/ EXC11: History of illegal substance use or alcohol abuse within the past 2 years. This does not apply to historical cannabis use that was formerly illegal in participant's state but is legal at Screening.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081027	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2081031	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2081032	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2081034	2020-05-29	AMENDMENT 1	Inclusion/Exclusion/ EXC08: Is a healthcare worker or a member of an emergency response team.	
US2081037	2020-05-29	AMENDMENT 1	Cohort Full	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081040	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2081043	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2081044	2020-06-01	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081047	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition; EXC20: Received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening Visit. Topical tacrolimus is allowed if not used <=14 days prior to Screening Visit	
US2081048	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2081050	2020-06-02	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081053	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2081055	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC09: Current use of any inhaled substance (eg, tobacco or cannabis smoke, nicotine vapors)	
US2081056	2020-06-03	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081060	2020-06-04	AMENDMENT 1	Inclusion/Exclusion/ EXC11: History of illegal substance use or alcohol abuse within the past 2 years. This does not apply to historical cannabis use that was formerly illegal in participant's state but is legal at Screening.	
US2081061	2020-06-04	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2081067	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	
US2081068	2020-06-11	AMENDMENT 1	Inclusion/Exclusion/ INC02: Understands and agrees to comply with the study procedures and provides written informed consent.	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081074	2020-06-15	AMENDMENT 1	Inclusion/Exclusion/ EXC23: History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine	
US2081078	2020-06-16	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0); EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2081079	2020-06-17	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2081082	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ EXC14: Diabetes mellitus	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081083	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2081084	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2081086	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2081089	2020-06-18	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081094	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2081095	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2081096	2020-06-19	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	
US2081098	2020-06-22	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081101	2020-06-22	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	
US2081102	2020-06-22	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2081105	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2081106	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	
US2081107	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ EXC15: Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081109	2020-06-23	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2081111	2020-06-24	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2081114	2020-06-24	AMENDMENT 1	Inclusion/Exclusion/ EXC15: Diagnosis of chronic pulmonary disease (eg, chronic obstructive pulmonary disease, asthma)	
US2081115	2020-06-24	AMENDMENT 1	Inclusion/Exclusion/ INC04: Body mass index (BMI) of 18 kg/m2 to 30 kg/m2 (inclusive) at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081122	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC07: Has a medical/psychiatric/occupational condition that may pose risk due to participation, or that could interfere with safety assessments or interpretation of results by investigator's judgment.	
US2081124	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	
US2081126	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC25: Diagnosis of malignancy within previous 10 years (excluding non-melanoma skin cancer)	
US2081127	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC12: Known history of hypertension, or systolic blood pressure > 150 mm Hg in participants in Cohort 1 or systolic blood pressure > 160 mm Hg in participants in Cohort 2 at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020

Listing 16.2.1.2
Screen Failure Subject
Subjects Screen Failed

Subject ID	Informed Consent Date	Protocol Version	Screen Failure Reason	If Other, Specify
US2081128	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC19: Current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition	
US2081130	2020-06-25	AMENDMENT 1	Inclusion/Exclusion/ EXC18: Grade 1 or higher toxicity on clinical safety laboratory testing at the Screening Visit (Day 0)	

* indicates re-screen subjects.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020102.sas 19NOV2020 01:22 Database Lock Date: 05NOV2020